HUAWEI WATCH GT 7 Series and HUAWEI WATCH D3: Spotlight Research on Cardiovascular Health and Blood Pressure Monitoring

Manila, Philippines – HUAWEI is advancing its contributions to cardiovascular health research, with studies involving its wearable devices gaining recognition at two international medical conferences: the 19th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in South Korea and the 31st International Society of Hypertension Scientific Meeting and 17th Emirates Cardiac Society Annual Conference (ISH-ECS) in Dubai.

Meanwhile, at the ISH-ECS 2026, HUAWEI showcased its latest blood pressure monitoring innovations, including the HUAWEI WATCH D3, and highlighted its collaboration with the ISH through the newly established Wearable Blood Pressure Technology Innovation Fund.

Together, these developments reflect HUAWEI's continued efforts to bridge medical research and consumer technology, bringing advanced cardiovascular monitoring capabilities closer to everyday users. Through its HUAWEI WATCH GT 7 Pro and WATCH D3, the company aims to make heart health and blood pressure monitoring more accessible while supporting greater awareness of cardiovascular health.

Advancing Research Through Wearable Technology

At APHRS 2026, research involving HUAWEI wearables was cited in the 2026 Asia Pacific Atrial Fibrillation Guidelines, highlighting the potential of HUAWEI wearables in clinical settings while underscoring the growing role of smart devices in supporting proactive heart health monitoring. The study explored the links between sleep apnea, arrhythmia, blood pressure, and cardiovascular events using data from HUAWEI devices, proving the technology's capability to further cardiovascular research.

Advancing Blood Pressure Monitoring Through Global Research

At the ISH-ECS 2026, HUAWEI also showcased its latest advancements in blood pressure monitoring in collaboration with the ISH through the Wearable Blood Pressure Technology Innovation Fund.

HUAWEI introduced its Minimally Disruptive Ambulatory Blood Pressure Monitoring (ABPM) research initiative at the conference. Developed in partnership with Ruijin Hospital, the study explores a hybrid approach that combines continuous photoplethysmography (PPG) monitoring with airbag-based blood pressure measurements to reduce reliance on cuff-based readings and make long-term blood pressure monitoring more comfortable and practical for users.

“Innovations like Minimally Disruptive ABPM and environmental monitoring reminders by HUAWEI Watch D3 may be inspiring for shaping a new direction on how future blood pressure management is automated and seamlessly embedded into daily life, via wearable devices,” said Professor Wang Jiguang, President of the Chinese Hypertension Association.

HUAWEI WATCH D3 and GT 7 Series: Advanced, All-in-One Health Tracking

The HUAWEI WATCH D3 and GT 7 Pro feature a one-tap Health Glance assessment, which analyzes crucial indicators like heart rate, heart rate variability (HRV), blood oxygen levels, arterial elasticity, and ECG data in a matter of seconds. The watch combines these metrics to generate a comprehensive report, helping users easily understand their overall health and spot potential risks early.

From early risk detection to continuous long-term management, HUAWEI remains committed to using smart technology to advance health awareness. By continuing to collaborate with global medical and research partners, HUAWEI aims to innovate digital health solutions and make advanced heart and blood pressure care accessible to everyone.

To learn more, visit HUAWEI’s official website or social media accounts (Facebook | Instagram).